The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Talecris Biotherapeutics

Is the IPO Window Open for Biotech and Pharma? Talecris and Anthera Aim to Find Out.

Biopharma IPOs come in pairs, apparently (a-pair-ently?).  A month ago, Cumberland and Emdeon created something that looked like an IPO window and now, Talecris Biotherapeutics and Anthera Pharmaceuticals have filed to go public:

If Anthera’s offering succeeds, I think we can officially declare IPOs back as a viable exit.

Update: Omeros, which has some late-stage spec pharma products as well as an early-stage CNS pipeline, and was the subject of IPO rumors a couple of weeks ago, has filed an amended S-1 indicating a $10-$12 per share price range.

He Loves Me, He Loves Me Not: CSL Gets Mixed Messages from Uncle Sam

Godward-He_Loves_Me%2C_He_Loves_Me_Not-1896Last week, CSL heard from the Federal Trade Commission that the agency is opposed to CSL’s proposed $3.1 billion merger with Talecris Biotherapeutics.

Don’t worry, CSL, Health and Human Services still loves you.  To the tune of a $180 million order for CSL’s H1N1 swine flu vaccine bulk antigen.  HHS will also fund the clinical trials.

Bookmark and Share

Follow

Get every new post delivered to your Inbox.

Join 126 other followers